|
Vannier, E; Kaser, A; Atkins, M B et al. (1999) Elevated circulating levels of soluble interleukin-1 receptor type II during interleukin-2 immunotherapy. Eur Cytokine Netw 10:37-42
|
|
Tilg, H; Dinarello, C A; Mier, J W (1997) IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol Today 18:428-32
|
|
Stoddart Jr, J H; Jasuja, R R; Sikorski, M A et al. (1996) Protease-resistant L-selectin mutants. Down-modulation by cross-linking but not cellular activation. J Immunol 157:5653-9
|
|
Sikorski, M A; Staunton, D E; Mier, J W (1996) L-selectin crosslinking induces integrin-dependent adhesion: evidence for a signaling pathway involving PTK but not PKC. Cell Adhes Commun 4:355-67
|
|
Tilg, H; Atkins, M B; Dinarello, C A et al. (1995) Induction of circulating interleukin 10 by interleukin 1 and interleukin 2, but not interleukin 6 immunotherapy. Cytokine 7:734-9
|
|
Tilg, H; Shapiro, L; Vannier, E et al. (1994) Induction of circulating antagonists to IL-1 and TNF by IL-2 administration and their effects on IL-2 induced cytokine production in vitro. J Immunol 152:3189-98
|
|
Tilg, H; Trehu, E; Atkins, M B et al. (1994) Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 83:113-8
|
|
Tilg, H; Trehu, E; Shapiro, L et al. (1994) Induction of circulating soluble tumour necrosis factor receptor and interleukin 1 receptor antagonist following interleukin 1 alpha infusion in humans. Cytokine 6:215-9
|
|
Trehu, E G; Isner, J M; Mier, J W et al. (1993) Possible myocardial toxicity associated with interleukin-4 therapy. J Immunother Emphasis Tumor Immunol 14:348-51
|
|
Tilg, H; Pape, D; Trehu, E et al. (1993) A method for the detection of erythrocyte-bound interleukin-8 in humans during interleukin-1 immunotherapy. J Immunol Methods 163:253-8
|
Showing the most recent 10 out of 21 publications
